OTC Markets OTCPK - Delayed Quote ? USD Mydecine Innovations Group Inc. (MYCOF) Follow Compare 0.0035 0.0000 (0.00%) As of October 21 at 4:00 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Mydecine Innovations Group Receives Two Notice of Allowances from USPTO for its MYCO-005 and MYCO-006 Family of Compounds VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces the issuance of two Notice of Allowances by the United States Patent and Trademark Office (USPTO) for compounds from the Company’s MYCO-005 and MYCO-006 families. MYCO-005 Notice of Allowance: Aza-Substituted Psil GlobeNewswire ? 8 months ago MYCOF 0.00% Mydecine Innovations Group Announces Director Resignation VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces that Neil Stevenson-Moore has resigned as a director of the Company. The Company would like to thank Mr. Stevenson-Moore for his contributions to the Company and wishes him well in this future endeavors. The Company GlobeNewswire ? 8 months ago MYCOF 0.00% Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound VANCOUVER, British Columbia, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a forefront biotechnology company dedicated to revolutionising mental health and addiction treatment, proudly announces the Company has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office (USPTO) for their MYCO-005 compound, "Novel Aza-Substituted Psilocin Analogs And Methods Of Synt GlobeNewswire ? 9 months ago MYCOF 0.00% Mydecine Announces Update Regarding the Special Access Program DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, wishes to clarify certain statements made in the Company’s news release of January 13, 2022 (the “Prior Release”) wherein the Company announced it would be launching the Special GlobeNewswire ? 10 months ago MYCOF 0.00% Canadian Securities Exchange Reports October 2023 Performance Figures Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for October 2023.October 2023 Operating StatisticsTrading volume of CSE-listed securities totaled 915 million shares;Trading value of CSE-listed securities was $352 million;CSE issuers completed 65 financings that raised an aggregate $113 million; andThe CSE welcomed listings from 11 new companies, including three fundamental changes of existing is Newsfile ? 10 months ago RECE.CN SSPLF ICS.CN Mydecine Innovations Group Files Prospectus Supplement, Announces Closing Under Share Subscription Agreements VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with: (i) its previously announced Common Share Subscription Agreement (the “Opensky Subscription Agre GlobeNewswire ? 11 months ago MYCOF 0.00% Mydecine Provides Q4 2023 Business Update VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD with psychedelic therapeutics, is pleased to address its shareholders and provide a general update on the Company's progress. The Company has spe GlobeNewswire ? 11 months ago MYCOF 0.00% Performance Overview Trailing total returns as of 10/22/2024, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index Return MYCOF S&P/TSX Composite index YTD -76.67% +17.76% 1-Year -96.76% +29.11% 3-Year -98.71% +16.35%
